Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/BF01991655 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The role of multimodality imaging in diabetic cardiomyopathy: a brief review.
Front Endocrinol (Lausanne)
January 2025
Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, United States.
Diabetic cardiomyopathy (DMCM), defined as left ventricular dysfunction in the setting of diabetes mellitus without hypertension, coronary artery disease or valvular heart disease, is a well-recognized entity whose prevalence is certainly predicted to increase alongside the rising incidence and prevalence of diabetes mellitus. The pathophysiology of DMCM stems from hyperglycemia and insulin resistance, resulting in oxidative stress, inflammation, cardiomyocyte death, and fibrosis. These perturbations lead to left ventricular hypertrophy with associated impaired relaxation early in the course of the disease, and eventually culminating in combined systolic and diastolic heart failure.
View Article and Find Full Text PDFThe Effects of Metformin on Weight Loss, Cardiovascular Health, and Longevity.
Cardiol Rev
December 2024
Department of Cardiology, Westchester Medical Center and New York Medical College, Valhalla, NY.
Metformin, a biguanide derived from Galega officinalis, was first synthesized by Werner and Bell in 1922. Metformin was approved for the treatment of diabetes by the US Food and Drug Administration in 1994. It has since become the most widely used oral antidiabetic agent.
View Article and Find Full Text PDFCardiovascular, Metabolic, and Safety Outcomes with Semaglutide by Baseline Age: Post Hoc Analysis of SUSTAIN 6 and PIONEER 6.
Diabetes Ther
January 2025
School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK.
Introduction: The high risk of cardiovascular events in people with type 2 diabetes increases with age. The cardiovascular effects of once-weekly subcutaneous and once-daily oral semaglutide versus placebo in people with type 2 diabetes at high cardiovascular risk were investigated in the SUSTAIN 6 and PIONEER 6 cardiovascular outcomes trials, respectively. It is unknown whether the effects of semaglutide are age dependent.
View Article and Find Full Text PDFContractile Effects of Semaglutide in the Human Atrium.
Pharmaceutics
August 2024
Institute for Pharmacology and Toxicology, Medical Faculty, Martin Luther University Halle-Wittenberg, Magdeburger Straße 4, D-06112 Halle (Saale), Germany.
Article Synopsis
- Semaglutide is a GLP-1 receptor agonist used for treating type 2 diabetes and obesity, and its effect on heart contraction strength was investigated.
- In experiments using isolated human atrial muscle, semaglutide demonstrated a positive inotropic effect, enhancing heart muscle contraction strength and faster relaxation.
- However, this effect was reduced when certain inhibitors were applied, and semaglutide did not show the same effect in mouse heart preparations, indicating that its action may be specific to human atrial tissue at therapeutic concentrations.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!